Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	744,051 shs	N/A
ALEC Alector	$2.35 -1.7%	$1.77	$0.87 ▼ $6.37	$237.85M	0.86	840,808 shs	460,985 shs
EDIT Editas Medicine	$2.57 -3.0%	$2.67	$0.91 ▼ $4.12	$231.09M	2.19	2.85 million shs	1.15 million shs
FENC Adherex Technologies	$8.87	$8.49	$3.96 ▼ $9.42	$246.68M	0.4	77,020 shs	31,949 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	+106.39%
ALEC Alector	-0.42%	+5.29%	+48.45%	+77.70%	-54.13%
EDIT Editas Medicine	-0.75%	-2.93%	+2.32%	+52.74%	-27.99%
FENC Adherex Technologies	-1.88%	+8.57%	+3.86%	+10.46%	+63.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALEC Alector	3.997 of 5 stars	3.1	2.0	0.0	4.5	3.2	2.5	0.0
EDIT Editas Medicine	4.2489 of 5 stars	3.1	4.0	0.0	4.3	1.9	2.5	0.6
FENC Adherex Technologies	2.1064 of 5 stars	3.5	1.0	0.0	0.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
ALEC Alector	2.29	Hold	$4.17	77.30% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	98.44% Upside
FENC Adherex Technologies	3.00	Buy	$13.33	50.32% Upside

Current Analyst Ratings Breakdown

Latest ACHL, EDIT, FENC, and ALEC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/15/2025	FENC Adherex Technologies	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
ALEC Alector	$81.13M	2.93	N/A	N/A	$0.70 per share	3.36
EDIT Editas Medicine	$32.31M	7.15	N/A	N/A	$0.21 per share	12.24
FENC Adherex Technologies	$47.54M	5.19	$0.03 per share	279.91	($0.27) per share	-32.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	N/A
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	11/5/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.42	N/A	N/A	N/A	-35.05%	N/A	-23.92%	11/6/2025 (Estimated)

Latest ACHL, EDIT, FENC, and ALEC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FENC Adherex Technologies	-$0.06	-$0.11	-$0.05	-$0.11	$9.52 million	$9.76 million
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
ALEC Alector	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
ALEC Alector	0.13	3.78	3.78
EDIT Editas Medicine	N/A	2.77	2.77
FENC Adherex Technologies	N/A	4.85	4.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
ALEC Alector	85.83%
EDIT Editas Medicine	71.90%
FENC Adherex Technologies	55.51%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
ALEC Alector	9.70%
EDIT Editas Medicine	2.10%
FENC Adherex Technologies	11.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
FENC Adherex Technologies	10	27.81 million	24.54 million	Optionable

ACHL, EDIT, FENC, and ALEC Headlines

Recent News About These Companies

DG Capital Management LLC Decreases Stock Position in Adherex Technologies Inc. $FENC

August 26 at 7:08 AM | marketbeat.com

HC Wainwright Issues Pessimistic Estimate for FENC Earnings

August 26 at 2:28 AM | marketbeat.com

HC Wainwright Issues Negative Estimate for FENC Earnings

August 24, 2025 | marketbeat.com

Analysts Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $13.33

August 24, 2025 | americanbankingnews.com

Adherex Technologies (NASDAQ:FENC) Receives Buy Rating from HC Wainwright

August 24, 2025 | americanbankingnews.com

Research Analysts Issue Forecasts for FENC Q4 Earnings

August 23, 2025 | americanbankingnews.com

Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Rating of "Buy" by Analysts

August 21, 2025 | marketbeat.com

Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript

August 19, 2025 | seekingalpha.com

FY2025 EPS Estimates for Adherex Technologies Cut by Wedbush

August 19, 2025 | marketbeat.com

Wedbush Forecasts Weaker Earnings for Adherex Technologies

August 19, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Adherex Technologies (NASDAQ:FENC) to "Buy"

August 19, 2025 | americanbankingnews.com

Adherex Technologies (NASDAQ:FENC) Raised to "Buy" at Wall Street Zen

August 18, 2025 | marketbeat.com

Adherex Technologies (NASDAQ:FENC) Releases Earnings Results, Misses Expectations By $0.05 EPS

August 17, 2025 | marketbeat.com

Craig Hallum Forecasts Strong Price Appreciation for Adherex Technologies (NASDAQ:FENC) Stock

August 17, 2025 | marketbeat.com

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates

August 14, 2025 | zacks.com

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

August 14, 2025 | globenewswire.com

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

August 11, 2025 | globenewswire.com

Wall Street Zen Downgrades Adherex Technologies (NASDAQ:FENC) to Hold

August 10, 2025 | marketbeat.com

Adherex Technologies Inc. (NASDAQ:FENC) Director Rosty Raykov Sells 10,000 Shares

August 6, 2025 | marketbeat.com

Adherex Technologies (FENC) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Insider Selling: Adherex Technologies Inc. (NASDAQ:FENC) Director Sells 10,000 Shares of Stock

August 6, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, EDIT, FENC, and ALEC Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Alector NASDAQ:ALEC

$2.35 -0.04 (-1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$2.35 0.00 (-0.21%)

As of 05:38 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.57 -0.08 (-3.02%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 -0.02 (-0.97%)

As of 05:48 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Adherex Technologies NASDAQ:FENC

$8.87 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$8.88 +0.01 (+0.06%)

As of 04:20 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time